MorphoSys AG (MPSYF)
USD 73.27
(2.1%)
USD 73.27
(2.1%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 635.93 Million EUR | 87.34% |
| 2022 | 339.45 Million EUR | 4.2% |
| 2021 | 325.79 Million EUR | 2.38% |
| 2020 | 318.2 Million EUR | 647.5% |
| 2019 | 42.56 Million EUR | 59422.91% |
| 2018 | 71.51 Thousand EUR | -18.53% |
| 2017 | 87.78 Thousand EUR | -59.79% |
| 2016 | 218.29 Thousand EUR | -2.98% |
| 2015 | 225 Thousand EUR | -10.6% |
| 2014 | 251.67 Thousand EUR | -15.72% |
| 2013 | 298.6 Thousand EUR | 305.68% |
| 2012 | 73.6 Thousand EUR | 0.0% |
| 2011 | 73.6 Thousand EUR | -42.31% |
| 2010 | 127.59 Thousand EUR | 290.55% |
| 2009 | 32.67 Thousand EUR | -32.87% |
| 2008 | 48.67 Thousand EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| 2004 | - EUR | 0.0% |
| 2003 | - EUR | 0.0% |
| 2002 | - EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 261.03 Million EUR | -58.95% |
| 2023 FY | 635.93 Million EUR | 87.34% |
| 2023 Q3 | 282.51 Million EUR | 0.5% |
| 2023 Q1 | 281.08 Million EUR | -17.2% |
| 2023 Q4 | 635.93 Million EUR | 125.1% |
| 2023 Q2 | 281.12 Million EUR | 0.01% |
| 2022 Q2 | 331.94 Million EUR | 1.16% |
| 2022 Q1 | 328.14 Million EUR | 0.72% |
| 2022 Q3 | 334.61 Million EUR | 0.8% |
| 2022 Q4 | 339.45 Million EUR | 1.45% |
| 2022 FY | 339.45 Million EUR | 4.2% |
| 2021 Q4 | 325.79 Million EUR | 0.47% |
| 2021 FY | 325.79 Million EUR | 2.38% |
| 2021 Q1 | 320.65 Million EUR | 0.77% |
| 2021 Q2 | 321.95 Million EUR | 0.4% |
| 2021 Q3 | 324.27 Million EUR | 0.72% |
| 2020 Q1 | 47.85 Million EUR | 12.41% |
| 2020 FY | 318.2 Million EUR | 647.5% |
| 2020 Q4 | 318.2 Million EUR | 589.48% |
| 2020 Q3 | 46.15 Million EUR | -2.04% |
| 2020 Q2 | 47.11 Million EUR | -1.55% |
| 2019 Q3 | 43.33 Million EUR | 8.67% |
| 2019 FY | 42.56 Million EUR | 59422.91% |
| 2019 Q1 | 40.35 Million EUR | 56324.34% |
| 2019 Q2 | 39.87 Million EUR | -1.18% |
| 2019 Q4 | 42.56 Million EUR | -1.77% |
| 2018 Q3 | 71.51 Thousand EUR | -18.06% |
| 2018 Q2 | 87.28 Thousand EUR | -0.57% |
| 2018 Q1 | 87.78 Thousand EUR | 0.0% |
| 2018 Q4 | 71.51 Thousand EUR | 0.0% |
| 2018 FY | 71.51 Thousand EUR | -18.53% |
| 2017 FY | 87.78 Thousand EUR | -59.79% |
| 2017 Q4 | 87.78 Thousand EUR | -29.94% |
| 2017 Q3 | 125.3 Thousand EUR | -7.27% |
| 2017 Q2 | 135.12 Thousand EUR | -38.1% |
| 2017 Q1 | 218.29 Thousand EUR | 0.0% |
| 2016 Q1 | 225 Thousand EUR | 0.0% |
| 2016 Q2 | 225 Thousand EUR | 0.0% |
| 2016 Q4 | 218.29 Thousand EUR | -2.98% |
| 2016 Q3 | 225 Thousand EUR | 0.0% |
| 2016 FY | 218.29 Thousand EUR | -2.98% |
| 2015 Q1 | 249.69 Thousand EUR | -0.79% |
| 2015 Q2 | 247.38 Thousand EUR | -0.93% |
| 2015 Q3 | 244.25 Thousand EUR | -1.27% |
| 2015 Q4 | 225 Thousand EUR | -7.88% |
| 2015 FY | 225 Thousand EUR | -10.6% |
| 2014 Q3 | 273.04 Thousand EUR | -2.3% |
| 2014 FY | 251.67 Thousand EUR | -15.72% |
| 2014 Q2 | 279.48 Thousand EUR | -6.4% |
| 2014 Q4 | 251.67 Thousand EUR | -7.83% |
| 2014 Q1 | 298.6 Thousand EUR | 0.0% |
| 2013 Q3 | 298.6 Thousand EUR | 305.68% |
| 2013 Q4 | 298.6 Thousand EUR | 0.0% |
| 2013 FY | 298.6 Thousand EUR | 305.68% |
| 2013 Q1 | 73.6 Thousand EUR | 0.0% |
| 2013 Q2 | 73.6 Thousand EUR | 0.0% |
| 2012 Q3 | 73.6 Thousand EUR | 0.0% |
| 2012 Q4 | 73.6 Thousand EUR | 0.0% |
| 2012 FY | 73.6 Thousand EUR | 0.0% |
| 2012 Q1 | 73.6 Thousand EUR | 0.0% |
| 2012 Q2 | 73.6 Thousand EUR | 0.0% |
| 2011 FY | 73.6 Thousand EUR | -42.31% |
| 2011 Q3 | 159.71 Thousand EUR | 9.74% |
| 2011 Q4 | 73.6 Thousand EUR | -53.91% |
| 2011 Q2 | 145.54 Thousand EUR | 3.75% |
| 2011 Q1 | 140.27 Thousand EUR | 9.94% |
| 2010 Q1 | 32.67 Thousand EUR | 0.0% |
| 2010 FY | 127.59 Thousand EUR | 290.55% |
| 2010 Q3 | 114.44 Thousand EUR | 250.3% |
| 2010 Q4 | 127.59 Thousand EUR | 11.49% |
| 2010 Q2 | 32.67 Thousand EUR | 0.0% |
| 2009 FY | 32.67 Thousand EUR | -32.87% |
| 2009 Q4 | 32.67 Thousand EUR | 0.0% |
| 2008 FY | 48.67 Thousand EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| 2004 FY | - EUR | 0.0% |
| 2003 FY | - EUR | 0.0% |
| 2002 FY | - EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ContraFect Corporation | 2.88 Million USD | -21973.323% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -1443.413% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -15327.925% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -158151.589% |
| SQZ Biotechnologies Company | 27.47 Million USD | -2214.923% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -27240.702% |
| Evofem Biosciences, Inc. | 43.37 Million USD | -1366.194% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -2036.357% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -66962.309% |
| Marizyme, Inc. | 18.71 Million USD | -3297.53% |
| Genus plc | 233.1 Million USD | -172.815% |
| Pharming Group N.V. | 171.54 Million USD | -270.709% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -71508.851% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -47231.051% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -84690.99% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -43869.03% |
| IMV Inc. | 28.88 Million USD | -2101.685% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -11138.826% |
| ONE Bio Corp. | 19.71 Million USD | -3125.624% |
| RVL Pharmaceuticals plc | 57.48 Million USD | -1006.181% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -100829.319% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -51670.809% |
| Biomind Labs Inc. | 735.54 Thousand USD | -86357.664% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | -840.133% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -4792.919% |
| Skye Bioscience, Inc. | 4.61 Million USD | -13678.89% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -176690.311% |
| Mesoblast Limited | 118.7 Million USD | -435.746% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -449265.048% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -10731.591% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -2472517.24% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -28058.775% |
| GB Sciences, Inc. | 1.75 Million USD | -36046.757% |
| MultiCell Technologies, Inc. | 202.58 USD | -313916588.716% |
| Alpha Cognition Inc. | 1.22 Million USD | -52009.72% |
| HST Global, Inc. | 98.31 Thousand USD | -646705.224% |
| CSL Limited | 12.18 Billion USD | 94.78% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Agentix Corp. | 50 Thousand USD | -1271764.856% |
| Halberd Corporation | 150 Thousand USD | -423854.952% |
| Enzolytics Inc. | 996.33 Thousand USD | -63726.977% |
| Resverlogix Corp. | 6.49 Million USD | -9697.141% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -248707.642% |
| argenx SE | 20 Million USD | -3079.662% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -1821.188% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| Bioxytran, Inc. | 1.92 Million USD | -32935.451% |
| Zenith Capital Corp. | 10.22 Thousand USD | -6219288.049% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -26422.337% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -277247.313% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -427693.687% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Genscript Biotech Corporation | 417.73 Million USD | -52.232% |
| Kadimastem Ltd | 891.22 Thousand USD | -71254.789% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -20914.286% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -3028.357% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -21601.305% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -469267.857% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -42444.372% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -254087.922% |
| Q BioMed Inc. | 4.1 Million USD | -15372.88% |
| LadRx Corporation | 33.6 Thousand USD | -1892218.122% |
| Cell Source, Inc. | 9.25 Million USD | -6771.844% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -83995.354% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | -1295.813% |
| Itoco Inc. | 228.37 Thousand USD | -278357.3% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -301325.49% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -255582.063% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -8891.227% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -12662.039% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -23377.377% |
| GeneThera, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -316889.885% |
| NovAccess Global Inc. | 2.19 Million USD | -28807.596% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | -13397.689% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -180641.182% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -8032.17% |
| SYBLEU INC | 477.5 Thousand USD | -133079.566% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -519028.513% |
| Rebus Holdings, Inc. | 310 Thousand USD | -205039.493% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -83995.354% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -13329.663% |
| Affymax, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -131213.946% |
| International Stem Cell Corporation | 4.17 Million USD | -15120.977% |
| CytoDyn Inc. | 30.07 Million USD | -2014.418% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -1018810.208% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -29059.174% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -7547.095% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -7307.483% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -40783.382% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -237188.219% |
| Neutra Corp. | 54.15 Thousand USD | -1174160.337% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -34650.406% |
| PureTech Health plc | 25.51 Million USD | -2392.68% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -51845.672% |
| IXICO plc | 472.02 Thousand USD | -134624.882% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -4002.525% |
| Gelesis Holdings, Inc. | 62.26 Million USD | -921.365% |
| CSL Limited | 12.18 Billion USD | 94.78% |
| Cellectis S.A. | 92.77 Million USD | -585.446% |